BRAINBox Solutions

BRAINBox Solutions is a private, clinical-stage diagnostics company developing an integrated, multi-modality test for mild traumatic brain injury (concussion). Its platform combines blood-based biomarkers—measurable on both lab systems and a proprietary point-of-care instrument—with tablet-based neurocognitive assessments, all integrated via an AI-driven algorithm to deliver diagnostic and prognostic information. Founded in 2017 and based in Raleigh, North Carolina, the company is advancing its lead program through a pivotal clinical trial (HeadSMART II), supported by $23 million in recent funding. BRAINBox aims to establish a new standard of objective care in the large and underserved TBI market.

Integrated multi-modality platform combining blood biomarker panels (for standard lab and proprietary point-of-care use) with tablet-based neurocognitive testing, synthesized by an AI-driven algorithm to provide diagnostic and prognostic scores for mild traumatic brain injury (mTBI).

The mTBI diagnostic space includes companies developing standalone blood tests (e.g., for biomarkers like GFAP/UCH-L1) and digital cognitive assessment tools. BRAINBox's key differentiator is its integrated, multi-modal platform combining both approaches, but it must demonstrate superior clinical utility and cost-effectiveness to compete effectively.